Objectives: Accurate and sufficiently detailed data on the economic burden of Clostridium difficile infection (CDI) are lacking. We performed a micro-costing study to determine the health resource utilization of patients with a first episode of CDI (fCDI) and those with a recurrent episode of CDI (rCDI).
Introduction
Clostridium difficile infection (CDI) frequently causes healthcareassociated infectious diarrhoea and is associated with significant morbidity, mortality and financial burden. [1] [2] [3] [4] [5] Recurrent CDI (rCDI) affects 20%-30% of metronidazole-or vancomycin-treated patients, requiring repeated and prolonged treatment. [6] [7] [8] CDI increases excess length of hospital stay, which is greater for both severe 9 and recurrent episodes. 5, [10] [11] [12] [13] This is the main driver for increased cost of treating rCDI. 12, 14 Newer CDI drugs preserving the indigenous gut flora have been introduced, such as fidaxomicin, 8, 15, 16 monoclonal antibodies directed against C. difficile toxin (bezlotoxumab) 17 and microbiome restoration therapies such as faecal microbiota transplant (FMT). [18] [19] [20] These and several other developmental agents are particularly beneficial in preventing further recurrences. 21 However, they have perceived high acquisition costs, limiting widespread adoption. Accurate measurement of the economic burden of CDI is critical for making policy decisions about the introduction of interventions that are effective in reducing primary disease and recurrence. Despite this, there are few accurate estimates of costs associated with management of initial and rCDI episodes. 5, 10, [12] [13] [14] [22] [23] [24] [25] [26] Prior studies use accounting rather than economic costs. These are crude costs, which risk underestimation due to difficulties in the accurate quantification of several variables such as overheads. Furthermore, it is unclear exactly which parameters are measured, with poor distinction between fixed and variable costs. Most hospital costs are fixed, e.g. capital expenditure, salaries, maintenance and utilities, accounting for 80% of hospital budget. 27 Variable costs, including drugs, patient/worker supplies, etc., represent a smaller proportion of the overall budget. Distinguishing between variable and fixed costs is important as any predicted cost saving following the introduction of an intervention may not be realized for some fixed costs. For example, staff expenditure is unlikely to reduce if more cases of CDI could be prevented. One study that did distinguish between these costs has been reported in Ireland; however, this was during an outbreak and did not measure costs resulting from rCDI. 28 Additionally, prior gross-costing studies reflect reimbursement amounts or tariffs using Health Resource Groups, which are estimates of average levels. These do not reflect true cost to the provider and healthcare system. In contrast, micro-costing allows the precise assessment of economic costs and reflects actual resource use.
We aimed to determine the actual cost of hospital resource use of patients with a first episode of CDI (fCDI) and those with rCDI using micro-costing methods to differentiate between fixed and variable components.
Patients and methods
A retrospective matched cohort study was performed from 1 April 2014 to 31 March 2017. This was conducted to compare costs and resource use of patients with rCDI with those of patients with fCDI (no recurrence; index case). The study included all adult and paediatric (.2 years) inpatients.
Setting
Data were analysed from inpatients of Guys and St Thomas' NHS Foundation Trust, a secondary and tertiary academic centre in central London with 1100 beds.
Study design
Matched controls were patients with fCDI with no subsequent positive C. difficile test or receipt of any antimicrobial for C. difficile, for 12 weeks after treatment of the initial episode. This group was matched to patients with rCDI by gender, age (+2 years) and date of C. difficile test (+8 weeks). Patients who died during hospital admission were excluded.
Patient investigation and management
Patients with diarrhoea (.2 unformed bowel movements/24 h) were tested for C. difficile using glutamate dehydrogenase; any positives were further tested with toxin enzyme immunoassay and PCR test simultaneously.
Adults with confirmed CDI (non-severe and severe) were treated with fidaxomicin (200 mg twice daily for 10 days) if able to tolerate oral medication. Patients ,18 years were treated with vancomycin (125 mg four times daily for 10 days). Patients with rCDI were treated with further fidaxomicin or with tapering vancomycin, depending on number of recurrences. 16 Patients with a second recurrence were offered FMT as previously described. 18 
Data collection
Clinical and microbiological data were collected from patient hospital records. Resource use and micro-costing data were obtained from the hospital Patient, Education and Research Costing System (PERCS) (IQVIA, London, UK). This costing engine includes patient-level data for all direct and indirect costs; full details on parameters measured can be found in Table S1 (available as Supplementary data at JAC Online).
The analysis is written from the provider perspective and does not assess indirect costs such as productivity losses due to illness-related disability and death. 10 
Statistical analysis
Analysis was performed using Prism 7 (GraphPad Software Inc., La Jolla, CA, USA). Results are presented using the mean (and SD), median (and IQR and/or 95% CI) or percentages, as appropriate. A paired Student's t-test was used to test statistical significance of variables between the fCDI and rCDI groups. A P value of ,0.05 was considered significant.
Consent
Patient consent was not required as the direct clinical care team collected only routine data, which were pseudo-anonymized.
Results
A total of 45 rCDI patients and 45 matched fCDI controls were included in the study. Both groups had identical gender and similar age distribution. Seventeen (38%) and 16 (36%) patients had CDI diagnosed within 2 days of admission in the fCDI group and the rCDI group, respectively.
There was a wide distribution of ribotypes amongst infected patients, with 28 different ribotypes identified across both groups. Notably, no patients in either group were infected with ribotype 027. However, significantly more patients with rCDI were infected with ribotype 078 (8/34, 24%) than those with fCDI (1/37, 3%); P " 0.0037.
The mean total length of hospital stay for rCDI patients was 33 days (95% CI 19-46) compared with 17 days (95% CI 12-21) for fCDI; P " 0.0259. Cumulative occupied bed days (combined total length of stay for all patients) for rCDI totalled 1475 compared with 763 for fCDI.
ICU admission was required for 20% of rCDI patients compared with 13% of fCDI patients, although this was not significant. Length of ICU stay was longer for rCDI patients than those with fCDI (mean 2.5 versus 0.7 days, respectively), but again this was not significant. Cumulative ICU days were 111 and 32 days for rCDI and fCDI, respectively. Table 1 summarizes the differences between the index patient group and the rCDI group.
Mean total variable costs for fCDI and rCDI were £2382 (95% CI 1750-3014) and £4683 (95% CI 3051-6311), respectively; P " 0.009. Mean total fixed costs for fCDI and rCDI were £10328 (95% CI 7555-13101) and £26438 (95% CI 16135-36742), respectively; P " 0.003. Mean total costs for fCDI and rCDI were £12710 (95% CI 9652-15769) and £31121 (95% CI 19792-42447), respectively; P , 0.002. Mean total fixed and variable costs for both patient groups are shown in Figure S1 . However, when mean costs were calculated per occupied bed day, there were no significant differences in either of the costing groups, although mean costs per day were higher in the rCDI group. Table 2 shows costing data for statistically significant categories in both patient groups. Table S2 details all costing categories.
Notable differences in costs of various categories were observed; within the variable costs group, drugs, pathology tests, sterile services and linen were all significantly higher for rCDI patients compared with fCDI patients. Similarly, within the fixed costs group, theatres, security, ward costs, therapies (physiotherapy, occupational therapy, speech and language therapy and hand therapy), medical pay, professional and technical pay, portering pay, board expenses, clinical audit, clinical coding, patient administration and support, departmental support, training and Tresman and Goldenberg 
Discussion
To our knowledge, this micro-costing study of patients with fCDI and rCDI provides for the first time a comprehensive measure of the total costs of treating patients in the UK. Unlike other studies that used accounting costs based on average tariffs, these data provide an accurate measure of the true burden of disease. Several parameters have not previously been measured and are often overlooked, e.g. variable costs such as catering, linen, blood products and sterile services as well as fixed costs such as security, patient transport and overheads. Prior studies risk significantly underestimating true financial burden due to failure to capture these parameters. For example, a recent UK-based multicentre study with a similar methodology estimated the cost of managing a patient with fCDI to be £6294 compared with £12710 in our study. 12 The same study estimated the cost of rCDI to be £7539 compared with our figure of £31121, which is .4-fold greater; however, this study estimated costs only for a defined 28 day period.
Both total fixed and variable costs were found to be significantly more for patients with rCDI when compared with those with fCDI. The following categories were all significantly more for the rCDI group: drugs, pathology tests, sterile services, linen, medical pay and overheads.
In the case of drugs, it is unlikely that difference in cost is related to more patients in the rCDI group receiving fidaxomicin (costing £1350 per course), because this is given as a first-line agent for all adult cases regardless of recurrence status in our institution. Similarly, bezlotoxumab was not available during the study period and as the cost of providing FMT is not captured by the PERCS system, this is also unlikely to account for the observed difference.
It is difficult to explain some of the differences that were observed to be significantly greater for many parameters. For example, we are unaware of any plausible reason why the costs for things such as security, clinical audit and coding, board expenses, training, overheads and building depreciation should be significantly greater for rCDI patients than for those with fCDI.
Consistent with previous studies showing that rCDI is associated with significantly increased healthcare use and cost than fCDI, the costs of treating rCDI in this study were driven largely by the extended duration of hospital stay. 5, 10, 12, 14, 22 In our study, patients with fCDI had a mean total length of stay of 17 days compared with 33 days for those with rCDI. When mean costs were calculated per day, the overall cost was greater for rCDI than for fCDI (£1743 versus £836/day, respectively).
As previously observed, we measured an increase in ICU stay for rCDI patients compared with fCDI patients. 10 However, one study based in the USA found that ICU stay decreased in patients with rCDI compared with fCDI (as did severity and risk of complications). 24 Although the overall distribution of ribotypes in our study is broadly representative of types seen across the UK, there were significant differences in the distribution of ribotypes amongst the two groups of patients. Ribotype 078 was particularly prevalent amongst rCDI patients in our study (24% compared with just 3% in the fCDI group). This is potentially important, because ribotype 078 has been associated with increased disease severity and excess mortality, with one study observing 25% mortality compared with 13% for all strains. 29 The cost of litigation resulting from medical negligence is often overlooked, but can amount to considerable sums. Nationally, the mean legal costs for successful claims mentioning CDI between 2001 and 2010 were £29649 (95% CI 22249-37048). 30 Our study includes payments to the Clinical Negligence Scheme for Trusts to NHS Resolution (who manage negligence claims against the NHS on behalf of member organizations).
There are several limitations to our study: it was single centre, data were collected retrospectively and only a modest number of patients were included. Since the introduction of fidaxomicin for all patients at our institution in 2012, the rate of recurrence has decreased significantly (from 16% to 3%), 16 limiting the number of patients that could be included in the study. Although data collection was retrospective, most parameters are objective and not liable to any systematic bias.
It is possible that recurrence rate was underestimated because only patients re-presenting to our (rather than other) hospitals were included, risking missing some rCDI cases. We relied on laboratory data to capture rCDI episodes because UK national policy discourages retesting of patients with positive samples in the previous 28 days.
Importantly, it is possible that other comorbidities influenced costs, as patients were not matched by non-CDI diagnosis or procedure. Similarly, we did not match on severity of CDI and other potentially confounding variables, e.g. PCR ribotype.
This study has demonstrated the significant costs associated with managing both patients with fCDI and those with rCDI in an endemic setting. Healthcare resource utilization and financial burden are substantial for both groups of patients, yet they are frequently underestimated. These data provide evidence to aid decision making on strategies to prevent and effectively manage CDI.
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